David Witt, MD

Current Trials

• Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

  HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028

  Recruiting Participants

  Lymphoma

• Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

  HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026

  Recruiting Participants

  Lung Cancer

• A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

  HIC ID2000031542RoleSub InvestigatorPrimary Completion Date01/31/2026

  Recruiting Participants

  Pancreatic Cancer

• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis

  HIC ID2000030933RoleSub InvestigatorPrimary Completion Date06/30/2024

  Recruiting Participants

  Myeloma

• A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

  HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026

  Recruiting Participants

  Lymphoma